Literature DB >> 22923001

Strategies for the treatment of restless legs syndrome.

Mark J Buchfuhrer1.   

Abstract

Restless legs syndrome (RLS) is a common neurological disorder of unknown etiology that is managed by therapy directed at relieving its symptoms. Treatment of patients with milder symptoms that occur intermittently may be treated with nonpharmacological therapy but when not successful, drug therapy should be chosen based on the timing of the symptoms and the needs of the patient. Patients with moderate to severe RLS typically require daily medication to control their symptoms. Although the dopamine agonists, ropinirole and pramipexole have been the drugs of choice for patients with moderate to severe RLS, drug emergent problems like augmentation may limit their use for long term therapy. Keeping the dopamine agonist dose as low as possible, using longer acting dopamine agonists such as the rotigotine patch and maintaining a high serum ferritin level may help prevent the development of augmentation. The α2δ anticonvulsants may now also be considered as drugs of choice for moderate to severe RLS patients. Opioids should be considered for RLS patients, especially for those who have failed other therapies since they are very effective for severe cases. When monitored appropriately, they can be very safe and durable for long term therapy. They should also be strongly considered for treating patients with augmentation as they are very effective for relieving the worsening symptoms that occur when decreasing or eliminating dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22923001      PMCID: PMC3480566          DOI: 10.1007/s13311-012-0139-4

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  146 in total

1.  Mirtazapine may have the propensity for developing a restless legs syndrome? A case report.

Authors:  Won-Myong Bahk; Chi-Un Pae; Jeong-Ho Chae; Tae-Youn Jun; Kwang-Soo Kim
Journal:  Psychiatry Clin Neurosci       Date:  2002-04       Impact factor: 5.188

2.  Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron.

Authors:  K A Lee; M E Zaffke; K Baratte-Beebe
Journal:  J Womens Health Gend Based Med       Date:  2001-05

3.  Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.

Authors:  Wayne A Hening; Richard P Allen; William G Ondo; Arthur S Walters; John W Winkelman; Philip Becker; Richard Bogan; June M Fry; David B Kudrow; Kurt W Lesh; Andreas Fichtner; Erwin Schollmayer
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

4.  Treatment of the restless legs syndrome with clonazepam.

Authors:  W B Matthews
Journal:  Br Med J       Date:  1979-03-17

Review 5.  Gabapentin enacarbil in restless legs syndrome.

Authors:  Giovanni Merlino; Anna Serafini; Simone Lorenzut; Martina Sommaro; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Drugs Today (Barc)       Date:  2010-01       Impact factor: 2.245

6.  Restless legs syndrome in end-stage renal disease.

Authors:  J W Winkelman; G M Chertow; J M Lazarus
Journal:  Am J Kidney Dis       Date:  1996-09       Impact factor: 8.860

7.  Pregabalin in restless legs syndrome with and without neuropathic pain.

Authors:  M Sommer; C G Bachmann; K M Liebetanz; J Schindehütte; T Tings; W Paulus
Journal:  Acta Neurol Scand       Date:  2007-05       Impact factor: 3.209

8.  Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome.

Authors:  Michael Saletu; Peter Anderer; Gerda Maria Saletu-Zyhlarz; Silvia Parapatics; Georg Gruber; Saba Nia; Bernd Saletu
Journal:  J Neural Transm (Vienna)       Date:  2010-01-05       Impact factor: 3.575

9.  Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.

Authors:  Diego García-Borreguero; Richard P Allen; Ralf Kohnen; Birgit Högl; Claudia Trenkwalder; Wolfgang Oertel; Wayne A Hening; Walter Paulus; David Rye; Arthur Walters; Juliane Winkelmann; Christopher J Earley
Journal:  Sleep Med       Date:  2007-06-01       Impact factor: 3.492

10.  Algorithms for the diagnosis and treatment of restless legs syndrome in primary care.

Authors:  Diego Garcia-Borreguero; Paul Stillman; Heike Benes; Heiner Buschmann; K Ray Chaudhuri; Victor M Gonzalez Rodríguez; Birgit Högl; Ralf Kohnen; Giorgio Carlo Monti; Karin Stiasny-Kolster; Claudia Trenkwalder; Anne-Marie Williams; Marco Zucconi
Journal:  BMC Neurol       Date:  2011-02-27       Impact factor: 2.474

View more
  21 in total

1.  Restless legs syndrome, sleep quality, and perceived cognitive impairment in adults with multiple sclerosis.

Authors:  Katie L J Cederberg; Brenda Jeng; Jeffer E Sasaki; Robert W Motl
Journal:  Mult Scler Relat Disord       Date:  2020-05-18       Impact factor: 4.339

2.  The treatment of sleep disorders.

Authors:  Rafael Pelayo; Emmanuel Mignot
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

Review 3.  Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

4.  Survivorship: sleep disorders, version 1.2014.

Authors:  Crystal S Denlinger; Jennifer A Ligibel; Madhuri Are; K Scott Baker; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H Ku; Elizabeth Kvale; Terry S Langbaum; Kristin Leonardi-Warren; Mary S McCabe; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

5.  Pramipexole induced psychosis in a patient with restless legs syndrome.

Authors:  Maria S Signorelli; Eliana Battaglia; Maria C Costanzo; Dario Cannavò
Journal:  BMJ Case Rep       Date:  2013-09-18

Review 6.  Efficacy of Pramipexole for the Treatment of Primary Restless Leg Syndrome: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

Authors:  Guang Jian Liu; Lang Wu; Song Lin Wang; Li Li Xu; Li Ying Chang; Yun Fu Wang
Journal:  Clin Ther       Date:  2015-11-11       Impact factor: 3.393

7.  The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome.

Authors:  Alon Y Avidan; Daniel Lee; Margaret Park; Mark J Jaros; Gwendoline Shang; Richard Kim
Journal:  CNS Drugs       Date:  2016-04       Impact factor: 5.749

8.  The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials.

Authors:  Neal Hermanowicz; Aaron Ellenbogen; Gordon Irving; Mark Buchfuhrer; Mark J Jaros; Gwendoline Shang; Richard Kim
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

9.  Physical activity, sedentary behavior, and restless legs syndrome in persons with multiple sclerosis.

Authors:  Katie L J Cederberg; Brenda Jeng; Jeffer E Sasaki; Tiffany J Braley; Arthur S Walters; Robert W Motl
Journal:  J Neurol Sci       Date:  2019-10-12       Impact factor: 3.181

10.  Feasibility and efficacy of a physical activity intervention for managing restless legs syndrome in multiple sclerosis: Results of a pilot randomized controlled trial.

Authors:  Katie L J Cederberg; Robert W Motl
Journal:  Mult Scler Relat Disord       Date:  2021-02-10       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.